摘要
目的:观察左炔诺孕酮宫内释放系统联合亮丙瑞林治疗子宫腺肌病患者的效果。方法:选取2020年8月至2023年9月该院收治的80例子宫腺肌病患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各40例。对照组予以亮丙瑞林治疗,研究组在对照组基础上联合左炔诺孕酮宫内释放系统治疗。比较两组临床疗效,治疗前后临床指标[子宫体积、子宫内膜厚度、月经失血图(PBAC)评分、视觉模拟评分法(VAS)评分]、性激素[卵泡刺激素(FSH)、雌二醇(E_(2))、黄体生成素(LH)]水平,以及不良反应发生率。结果:研究组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);治疗后,两组子宫体积、子宫内膜厚度均小于治疗前,且研究组小于对照组,两组PBAC、VAS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组FSH、LH、E_(2)水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:左炔诺孕酮宫内释放系统联合亮丙瑞林治疗子宫腺肌病患者可提高治疗总有效率,改善临床指标水平,降低性激素水平,效果优于单纯亮丙瑞林治疗。
Objective:To observe effects of levonorgestrel-releasing intrauterine system combined with Leuprorelin in treatment of patients with adenomyosis.Methods:A prospective study was conducted on 80 patients with adenomyosis admitted to the hospital from August 2020 to September 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with Leuprorelin,while the study group was treated with Levonorgestrel-releasing intrauterine system on the basis of that of the control group.The clinical efficacy,the levels of clinical indicators [uterine volume,endometrial thickness,menstrual blood loss map(PBAC)score,visual analogue scale(VAS) score] and sex hormones [follicle stimulating hormone(FSH),estradiol(E_(2)),luteinizing hormone(LH)] before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 92.50%(37/40),which was higher than 75.00%(30/40) in the control group,and the difference was statistically significant(P<0.05).After the treatment,the uterine volume and the endometrial thickness of the two groups were smaller than those before the treatment,and those in the study group were smaller than those in the control group;the PBAC and VAS scores of the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of FSH,LH and E_(2) in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Levonorgestrel-releasing intrauterine system combined with Leuprorelin in the treatment of the patients with adenomyosis can improve the total effective rate of treatment,improve the levels of clinical indicators and reduce the levels of sex hormones.Moreover,it is superior to simple Leuprorelin treatment.
作者
陈超娟
姚金英
CHEN Chaojuan;YAO Jinying(Department of Gynecology of Baofeng County People’s Hospital,Pingdingshan 467400 Henan,China)
出处
《中国民康医学》
2025年第5期79-81,共3页
Medical Journal of Chinese People’s Health
关键词
左炔诺孕酮宫内释放系统
亮丙瑞林
子宫腺肌病
临床指标
性激素
不良反应
Levonorgestrel-releasing intrauterine system
Leuprorelin
Adenomyosis
Clinical indicator
Sex hormone
Adverse reaction
